The FDA has approved Rexin-G™ (Epeius Biotechnologies), the world’s first tumor-targeted injectable gene therapy vector, as an orphan drug for pancreatic cancer.
Epeius has executed a screening agree ment with the National Cancer Institute to study the drug. The goal is to develop and commercialize the first effective targeted delivery system that can be injected directly into a vein to deliver genes and molecular therapeutics, preferentially, to cancerous tumors that have spread throughout the body without eliciting systemic side effects or organ damage.
Rexin-G™ is the first targeted inject-able gene therapy vector that has been approved by both the U.S. FDA and the Philippine FDA counterpart for use in phase I and II cancer clinical trials.
